The stock of Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) is a huge mover today! About 172,703 shares traded hands or 334.44% up from the average. Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) has declined 31.18% since April 21, 2016 and is downtrending. It has underperformed by 36.51% the S&P500.
The move comes after 7 months positive chart setup for the $23.26 million company. It was reported on Nov, 23 by Barchart.com. We have $2.77 PT which if reached, will make NASDAQ:PRAN worth $1.40M more.
According to Zacks Investment Research, “Prana Biotechnology was established to commercialize research into Alzheimer’s disease and other major age-related degenerative disorders. Their mission is to develop diagnostic and therapeutic drugs to treat the central disease pathways that cause degeneration of the brain as the aging process progresses. Prana’s technology has emerged from its researchers at prominent international institutions such as Massachusetts General Hospital at Harvard Medical School and the University of Melbourne.”
More notable recent Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) news were published by: Marketwatch.com which released: “Prana Biotechnology Ltd. ADR” on November 16, 2010, also Quotes.Wsj.com with their article: “DOW JONES, A NEWS CORP COMPANY” published on February 11, 2011, Fool.com published: “Down 70%: Is Prana Biotechnology Ltd. a Buy?” on March 31, 2014. More interesting news about Prana Biotechnology Limited (ADR) (NASDAQ:PRAN) were released by: Seekingalpha.com and their article: “Phase II Results Approaching For Prana’s PBT2 In Alzheimer’s Dementia And …” published on November 15, 2013 as well as Fool.com‘s news article titled: “New Huntington Disease Drug Is Safe, but Is It Effective?” with publication date: February 19, 2014.
PRAN Company Profile
Prana Biotechnology Limited, incorporated on November 11, 1997, is a development-stage medical biotechnology company. The Firm is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer’s disease, Huntington disease, Parkinson’s disease and other neurological disorders. The Company’s lead product candidates are PBT2 and PBT434. The Company’s lead drug candidate PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases. The Firm also has advanced a drug candidate for Parkinson’s disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. The Company’s other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders. PBT2 is a small molecule that reversibly binds and transports copper and zinc within neurons and across synapses.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.